Charles River Buys Cognate BioServices for $875 Million

Charles River Laboratories is acquiring Cognate BioServices, a Baltimore, Md.-based cell and gene therapy contract development and manufacturing firm for $875 million.

The Cognate BioServices acquisition will provide biopharmaceutical clients “an integrated solution to help accelerate their cell and gene therapy programs from discovery and nonclinical development through commercialization,” said Charles River CEO James Foster.

Cognate is expected to generate revenue of approximately $140 million in 2021 and to grow by at least 25 percent annually over the next five years, reflecting the overall growth in cell and gene therapies.